# Title

 Food and Drugs. PART 822â€”POSTMARKET SURVEILLANCE


# ID

 CFR-2018-title21-vol8.Pt. 822


# Structured Analysis Summary

| Type        | Values                                                                                                            |
|:------------|:------------------------------------------------------------------------------------------------------------------|
| Constraints | ['before', 'more than', 'within', 'greater than', 'after', 'prior to']                                            |
| Duration    | ['1.0 year', '30.0 day', '72.0 hour', '2.0 year', '60.0 day', '36.0 month']                                       |
| Condition   | ['until', 'unless and until', 'unless', 'where', 'as soon as', 'subject to', 'when', 'if']                        |
| Entities    | ['Surveillance and Biometrics', 'G112', 'Food', 'Rm', 'Research', 'Beltsville, MD', 'Unique', 'Guidance', 'G609'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                                          |
|:--------------|:-------------------------------------------------------------------------------------------------------------------------------------------------|
| more than     | to be implanted in the human body for more than 1 year; or (c) The device is intended                                                            |
| within        | of the device: (i) The lot or batch within which a device was manufactured; (ii) The serial                                                      |
| more than     | to be implanted in the human body for more than 1 year; or (c) The device is intended                                                            |
| before        | to define the scope of a surveillance order. before                                                                                              |
| after         | device, as your device goes to market, or after your device has been marketed for a period                                                       |
| within        | must submit your plan to conduct postmarket surveillance within 30 days of the date you receive the                                              |
| greater than  | If we believe that a prospective period of  greater than 36 months is necessary to address the surveillance                                      |
| within        | We will review your submission  within  60 days of receipt.                                                                                      |
| after         | to make changes to my postmarket surveillance plan after  you have approved it?                                                                  |
| before        | You must receive our approval in writing  before making changes in your plan that will affect                                                    |
| after         | in accordance with the Freedom of Information Act. after                                                                                         |
| after         | to protect trade secret and confidential commercial information after  your plan is approved.                                                    |
| within        | your plan to conduct postmarket surveillance to us within 30 days from receipt of the order (letter)                                             |
| after         | What are my responsibilities  after  my postmarket surveillance plan has been approved?                                                          |
| after         | your device in accordance with your approved plan. after                                                                                         |
| prior to      | manner; and (e) Any information that we request prior to your submission of a report or in response                                              |
| within        | You must notify us  within 30 days of any change in ownership of                                                                                 |
| within        | You must notify us  within 30 days of the date of your decision                                                                                  |
| after         | all records for a period of 2 years after we have accepted your final report, unless we                                                          |
| within        | the new sponsor or investigator and notify us within 10 working days of the effective date of                                                    |
| within        | This information must be produced  within  72 hours of the initiation of the inspection.                                                         |
| prior to      | generally will redact information pertaining to individual subjects prior to  copying those records, unless there are extenuating circumstances. |


## Duration

| Duration   | Context                                                                                                                                                                                                                                                   |
|:-----------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.0 year   | This part implements section 522 of the Federal Food, Drug, and Cosmetic Act (the act) by providing procedures and requirements for postmarket surveillance of class II and class III devices that meet any of the following criteria:                    |
|            |               (a) Failure of the device would be reasonably likely to have serious adverse health consequences;                                                                                                                                           |
|            |               (b) The device is intended to be implanted in the human body for more than 1 year; or                                                                                                                                                       |
|            |               (c) The device is intended to be used outside a user facility to support or sustain life.                                                                                                                                                   |
| 1.0 year   | We have the authority to order postmarket surveillance of any class II or class III medical device, including a device reviewed under the licensing provisions of section 351 of the Public Health Service Act, that meets any of the following criteria: |
|            |               (a) Failure of the device would be reasonably likely to have serious adverse health consequences;                                                                                                                                           |
|            |               (b) The device is intended to be implanted in the human body for more than 1 year; or                                                                                                                                                       |
|            |               (c) The device is intended to be used to support or sustain life and to be used outside a user facility.                                                                                                                                    |
| 30.0 day   | You must submit your plan to conduct postmarket surveillance within 30 days of the date you receive the postmarket surveillance order.                                                                                                                    |
| 36.0 month | We may order prospective surveillance for a period up to 36 months; longer periods require your agreement.                                                                                                                                                |
| 36.0 month | If we believe that a prospective period of greater than 36 months is necessary to address the surveillance question, and you do not agree, we will use the Medical Devices Dispute Resolution Panel to resolve the matter.                                |
| 36.0 month | The 36-month period refers to the surveillance period, not the length of time from the issuance of the order.                                                                                                                                             |
| 60.0 day   | We will review your submission within 60 days of receipt.                                                                                                                                                                                                 |
| 30.0 day   | You must submit your plan to conduct postmarket surveillance to us within 30 days from receipt of the order (letter) notifying you that you are required to conduct postmarket surveillance of a device.                                                  |
| 30.0 day   | You must notify us within 30 days of any change in ownership of your company.                                                                                                                                                                             |
| 30.0 day   | You must notify us within 30 days of the date of your decision to close your business.                                                                                                                                                                    |
| 2.0 year   | You, the designated person, and your investigators must keep all records for a period of 2 years after we have accepted your final report, unless we specify otherwise.                                                                                   |
| 72.0 hour  | This information must be produced within 72 hours of the initiation of the inspection.                                                                                                                                                                    |


## Condition

| Condition        | Context                                                                                                                     |
|:-----------------|:----------------------------------------------------------------------------------------------------------------------------|
| when             | that identifies one or more of the following when included on the label of the device: (i)                                  |
| if               | How will I know  if  I must conduct postmarket surveillance?                                                                |
| subject to       | We will specify the device(s)  subject to the surveillance order and the reason that we                                     |
| as soon as       | We will notify you  as soon as we have determined that postmarket surveillance of your                                      |
| if               | What should I do  if I do not agree that postmarket surveillance is                                                         |
| if               | you may request review of our decision by: if                                                                               |
| where            | When,  where , and how must I submit my postmarket                                                                          |
| if               | The plan objective(s) addressing the surveillance question(s) ident if ied in our order; (b) The subject of                 |
| if               | collection plan and forms; (i) The consent document, if  applicable;                                                        |
|                  |               (j) Institutional Review Board information,                                                                   |
| if               | collection plan and forms; (i) The consent document, if  applicable;                                                        |
|                  |               (j) Institutional Review Board information,                                                                   |
| if               | collection plan and forms; (i) The consent document, if  applicable;                                                        |
|                  |               (j) Institutional Review Board information,                                                                   |
| when             | What should I consider  when  designing my plan to conduct postmarket surveillance?                                         |
| if               | You should consider what,  if any, patient protection measures should be incorporated into                                  |
| when             | operating characteristics, and intended use of your device when  designing a surveillance approach.                         |
| where            | be incorporated and the document number and pages where  the information is located.                                        |
| if               | What are the consequences  if I fail to submit a postmarket surveillance plan,                                              |
| if               | What must I do  if I want to make changes to my postmarket                                                                  |
| if               | What recourse do I have  if  I do not agree with your decision?                                                             |
| if               | us about the content of your plan or if  we disapprove your plan, or                                                        |
| if               | us about the content of your plan or if  we disapprove your plan, or                                                        |
| if               | us about the content of your plan or if  we disapprove your plan, or                                                        |
| until            | We consider the content of your submission confidential  until  we have approved your postmarket surveillance plan.         |
| unless           | surveillance will generally transfer to the new owner, unless you and the new owner have both agreed                        |
| where            | (described in subpart G of this part) and where  the records will be kept.                                                  |
| subject to       | If I stop marketing the device  subject to  postmarket surveillance, what must I do?                                        |
| if               | surveillance in accordance with your approved plan even if  you no longer market the device.                                |
| unless           | you must continue to conduct the postmarket surveillance unless we notify you that you may stop your                        |
| unless and until | must comply with the requirements of this part unless and until  we grant an exemption for your device.                     |
| if               | (b) Signed agreements from each of your investigators, if your surveillance plan uses investigators, stating the commitment |
| unless           | years after we have accepted your final report, unless  we specify otherwise.                                               |
| if               | What must I do with the records  if the sponsor of the plan or an investigator                                              |
| where            | FDA employees to enter and inspect any facility where  the device is held or                                                |
| where            | FDA employees to enter and inspect any facility where  the device is held or                                                |
| unless           | to individual subjects prior to copying those records, unless  there are extenuating circumstances.                         |
| if               | are likely to be interested in such records if we have reason to believe that required reports                              |
| when             | we may ask you to submit additional information when we believe that the information is necessary for                       |


## Entities

| Entities                    | Context                                                                                                                            |
|:----------------------------|:-----------------------------------------------------------------------------------------------------------------------------------|
| Food                        | Food  and Drugs.                                                                                                                   |
| Unique                      | (o)  Unique device identifier (UDI) means an identifier that adequately                                                            |
| Surveillance and Biometrics | Requesting a meeting with the Director, Office of Surveillance and Biometrics , who generally issues the order for postmarket      |
| Research                    | regulated by the Center for Biologics Evaluation and Research , send three copies of your submission to                            |
| Research                    | regulated by the Center for Biologics Evaluation and Research , send three copies of your submission to                            |
| Rm                          | 71,  Rm .                                                                                                                          |
| G112                        | G112 , Silver Spring, MD 20993-0002.                                                                                               |
| Research                    | regulated by the Center for Drug Evaluation and Research , send three copies of your submission to                                 |
| Research                    | regulated by the Center for Drug Evaluation and Research , send three copies of your submission to                                 |
| Beltsville, MD              | Research, Food and Drug Administration, 5901-B, Ammendale Rd., Beltsville, MD  20705-1266.                                         |
| G609                        | G609 , Silver Spring, MD 20993-0002.                                                                                               |
| Guidance                    | Guidance documents that discuss our current thinking on preparing                                                                  |
| Surveillance and Biometrics | Center for Devices and Radiological Health, Office of Surveillance and Biometrics , 10903 New Hampshire Ave., Bldg.                |
| Guidance                    | Guidance documents represent our current interpretation of, or policy                                                              |
| Surveillance and Biometrics | Requesting a meeting with the Director, Office of Surveillance and Biometrics , Center for Devices and Radiological Health (CDRH), |


